WHO Calls for Greater Action to Eliminate Hepatitis
The regimen posted 93.9% sustained virologic response in 905 patients, nearly matching Epclusa and supporting a shorter treatment course, Atea said.
- On Tuesday, Atea Pharmaceuticals announced positive topline results from its pivotal Phase 3 trial, C-BEYOND, evaluating the once-daily bemnifosbuvir and ruzasvir regimen for treating chronic hepatitis C virus on World Hepatitis Day.
- Roughly 4 million people in the U.S. live with chronic HCV, a condition that can progress to cirrhosis, end-stage liver disease, or liver cancer if left untreated, making new treatment options critical.
- Statistical non-inferiority was confirmed for BEM/RZR against sofosbuvir and velpatasvir , with data from 905 patients showing the regimen achieved a 93.9% sustained virologic response rate in the mITT population.
- Dr. Eric Lawitz, Clinical Professor of Medicine at UT Health San Antonio and the Texas Liver Institute, called the 8-week regimen a "meaningful step forward" for HCV care, noting it could streamline prescribing and accelerate test-and-treat strategies.
- Atea expects to share results from its second Phase 3 trial, C-FORWARD, in early 2027, while the World Health Organization aims to reduce new hepatitis infections to just over 500,000 annually by 2030.
20 Articles
20 Articles
On the occasion of the World Hepatitis Day on 28 July, the Wiener Gesundheitsverbund draws attention to the importance of vaccination, early detection and treatment of viral hepatitis. Austria and the world are struggling with a massive liver problem. Every 30 seconds, a human being dies from chronic virus-related hepatitis. The situation is also serious in this country: 25 to 30 percent of Austrians are affected by fatty liver disease according…
More than 845 new cases of hepatitis A were reported in 2025, a growth of 265% compared to 2024. The increase is associated with person-to-person transmission and sexual contact.
Zeit Online
Here you will find information on the topic "World Hepatitis Day". Read now "WHO calls for more use in the fight against hepatitis B and C.
Hepatitis B and C Continue to Affect Thousands in Afghanistan, WHO Warns
The World Health Organization (WHO) has warned that hepatitis B and C infections continue to affect thousands of people in Afghanistan, with an estimated 59,333 cases recorded in 2025. The post Hepatitis B and C Continue to Affect Thousands in Afghanistan, WHO Warns appeared first on KabulNow.
Coverage Details
Bias Distribution
- 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
